Solid Biosciences LLC

Yahoo Finance • 12 months ago

Solid Biosciences Announces $109 Million Private Placement

Solid Biosciences Inc. CHARLESTOWN, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced tha... Full story

Yahoo Finance • last year

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President... Full story

Yahoo Finance • last year

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

– Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age – CHARLESTOWN, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences co... Full story

Yahoo Finance • last year

Solid Biosciences to Participate at Jefferies London Healthcare Conference

CHARLESTOWN, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President... Full story

Yahoo Finance • last year

Solid Biosciences Provides Third Quarter Business Update and Financial Results

– IND submission for SGT-003 for patients with Duchenne muscular dystrophy in Q4 2023 – – Strengthened management team with appointment of Dr. Gabriel Brooks as CMO – – Company ends third quarter with approximately $142.9 million in cash... Full story

Yahoo Finance • last year

Solid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer

- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both neuromuscular and cardiac diseases - CHARLESTO... Full story

Yahoo Finance • last year

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief... Full story

Yahoo Finance • last year

Solid Biosciences Provides Second Quarter Business Update and Financial Results

– On track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Executed licensing agreement for development and commercialization of gene therapies in certain f... Full story

Yahoo Finance • 2 years ago

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

— Oral presentation highlighting data from multiple animal models demonstrated administration of AVB-202 resulted in frataxin (FXN) expression in cardiac and central nervous system (CNS) tissues with a favorable safety profile and may impr... Full story

Yahoo Finance • 2 years ago

Solid Biosciences Provides First Quarter Business Update and Financial Results

Solid Biosciences Inc. – Company remains on track to submit IND in Q4 2023 for SGT-003, a next-generation gene therapy for patients with Duchenne muscular dystrophy (Duchenne) – – Company ends first quarter with approximately $185.5 mill... Full story

Yahoo Finance • 2 years ago

Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

CHARLESTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Solid management will partici... Full story

Yahoo Finance • 2 years ago

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chie... Full story

Yahoo Finance • 2 years ago

Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results

- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for S... Full story

Yahoo Finance • 2 years ago

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief... Full story

Yahoo Finance • 2 years ago

Solid Biosciences to Present at Barclays Global Healthcare Conference

CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief... Full story

Yahoo Finance • 2 years ago

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief... Full story

Yahoo Finance • 2 years ago

Pathway Development Consortium Announces Publication in Human Gene Therapy on the Application of FDA’s Accelerated Approval Pathway for AAV Gene Therapies for Patients with Duchenne Muscular Dystrophy

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duch... Full story

Yahoo Finance • 2 years ago

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Research collaboration to target severe form of genetic dilated cardiomyopathy Collaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac therapyCollaboration allows Phlox Therapeutics to lever... Full story

Yahoo Finance • 2 years ago

Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases

– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection and transition manufacturing process to... Full story

Yahoo Finance • 2 years ago

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced the grant of inducement awards to i... Full story